Platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists have been highly effective inhibitors of platelet aggregation in preclinical studies and in clinical trials. However, decreased platelet counts have been documented in preclinical studies and in some patients receiving GPIIb/IIIa antagonists. We evaluated changes in platelet kinetics and fate in dogs receiving the GPIIb/IIIa receptor antagonist RPR 109891 orally for 4 days. Dogs receiving RPR 109891 had a 22-52% decrease in platelet count with the nadirs at 3-5 days after initiation of treatment. Platelet survival time was reduced by 19%, and platelet half-life was reduced by 63%. Indium-111-labeled platelets were rapidly cleared from the blood within 1 hour after administration of RPR 109891 on treatment days 1 and 2. This clearing was associated with a sharp increase in radioactivity in spleen but not in liver or lung. Platelet clearance was markedly attenuated on treatment days 3 and 4. Platelet counts returned to baseline within 1 week after discontinuation of treatment. These data indicate that RPR 109891 causes rapid and selective sequestration of platelets in the spleen.
Acuirre FV, Topol EJ, Ferguson JJ, Anderson K., Blankenship JC, Heuser RR, Sigmon K., Taylor M., Gottlieb R. (1995). Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation91: 2882-2891.
2.
Alexander JH , Harrington RA (1998). Recent antiplatelet drug trails in the acute coronary syndromes—Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drug56: 965-976.
3.
Badenhorst PN , Lotter MG, Heyns AD, Van Reenan OR, Herbst C., Peters H., Kotze HF, Duyvene LJ, Minnaar PC (1982). The influence of the collection injury on the survival and distribution of indium-111-labeled canine platelets. Br J Haematol52: 233-240.
4.
Badenhorst PN, Peters H. (1986). Methodology of platelet imaging. In: Platelet Kinetics and Imaging, Heyns AP, Badenhorst PN, Lotter MG (eds). CRC Press, Boca Raton, FL, pp 159-168.
5.
Bednar B., Cummingham ME, McQueen CF (1997). Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartatic acid ligands in binding to glycoprotein IIb/IIIa on platelets. Cytometry28: 58-65.
6.
Belcher EH, Berlin NI, Eernisse JG, Garby L., Heimpel H., Lea M., Lewis SM, McIntyre PA, Mollison PI, Murphy EA, Najean Y., Pettit JE, Szuri L. (1977). Recommended methods for radioisotope platelet survival studies. Blood50: 1137-1144.
7.
Cannon C., McCabe CH, Borzak S. (1997). Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation97: 340-349.
8.
Collier BS (1998). Platelet IIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest99: 1467-1471.
9.
Coller BS (1997). GPIIb/IIIa antagonists: Pathophysiology and therapeutic insights from c7E3 Fab. Thromb Haemostasis23: 730-736.
10.
Collier BS, Folts JD, Scudder LE, Smith SR (1986). Antithrombotic effects of a monoclonal antibody to the platelet glycoprotein IIb/ IIIa receptor in an experimental animal model. Blood68: 783-786.
11.
Dore M., Hawkins HK, Entman Smith CW (1993). Production of a monoclonal antibody against canine GMP-140 (P-selectin) and studies of its vascular distribution in canine tissues . Vet Pathol30: 213-222.
12.
Du X., Ginsberg MH (1997). Integrin αIIβ3 and platelet function. Thromb Haemostasis78: 96-100.
Escolar G., Leistikow E., White JG (1989). The fate of the open canalicular system in surface and suspension-activated platelets. Blood74: 1983-1988.
15.
Foster RH, Wiseman LR (1998). ABCIXIMAB—A review of its use in ischemic heart disease. Drugs56: 629-665.
16.
Gawaz M., Ruf A., Neumann FJ, Pogatsa-Murry G., Dickfeld T., Zohlnhofer D., Schomig A. (1998). Effects of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemostasis80: 994-1001.
17.
Giugliano RP (1998). Drug-induced thrombocytopenia—Is it a serious concern for glycoprotein IIbIIIa receptor inhibitors. J Thromb Thrombolysis5: 191-202.
18.
Greenberg JP , Packham MA, Guccione MA, Guccione MA, Rand ML, Reimers HJ, Mustard JF (1979). Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood53: 916-922.
19.
Gulba DC, Huber K., Moll S., Dietz R. (1998). Platelet inhibition-New agents, new strategies, new trails. Fibrinolysis Proteolysis12: 13-23.
20.
Hubert M., Kunicki TJ, Bihour C., Winckler J., Nurden AT (1996). Visualization of activation-dependent epitopes on glycoprotein IIb/ IIIa complexes of platelets stimulated by thrombin-immunogold staining of ultrathin sections. Semin Thromb Haemostasis22: 279-288.
21.
Hughes A., Tonks RS (1962). Intravascular platelet clumping in rabbits. J Pathol Bacteriol84: 379-390.
22.
Itoh H., Cicala C., Douglas GJ, Page CP ( 1997). Platelet accumulation induced by bacterial endotoxin in rats. Thromb Res83: 405-419.
23.
Kotze HF, van Wyk V., Badenhorst PN, Heyns du P., Roodt JP, Lotter MG (1993). Influence of platelet membrane sialic acid and platelet-associated IgG on aging and sequestration of blood platelets in baboons . Thromb Haemostasis70: 676-680.
24.
Kotze HF, Wessels P., Peters H. (1986). Kinetics, redistribution, and sites of sequestration of normal platelets. In: Platelet Kinetics and Imaging, Heyns AP, Badenhorst PN, Lotter MG (eds). CRC Press, Boca Raton, FL, pp 107-123.
25.
Kristensen AT, Weiss DJ, Klausner J. (1994). Detection of antiplatelet antibody in the dog: Comparison of microscopic and fluorescence-activated cell sorter detection methods. Am J Vet Res55: 1111-1114.
26.
Leistikow EA , Barnhart MI, Escolar G., White J. (1990). Receptor-ligand complexes are cleared to the open canalicular system of surface-activated platelets . Br J Haematol74: 93-100.
Mak KH, Tan Ath, Chan C., Koh TH, Topol EJ (1998). The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine. Jpn Circ J62: 233-243.
29.
Packhan MA, Guccione MA, Kinlough-Rathbone RL, Mustard JF (1980). Platelet sialic acid and platelet survival after aggregation by ADP. Blood56: 876-883.
30.
Peter K., Schwarz M., Ylanne J., Kohler B., Moser M., Nordt T., Salbach P., Kubler W., Bode C. ( 1998). Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (α 2bβ3) inhibitors. Blood92: 3240-3249.
31.
Phillips DR , Charo IF, Parise LV, Fitzgerald LA (1988). The platelet membrane glycoprotein IIb-IIIa complex. Blood71: 831-843.
32.
Schmitz G., Rothe G., Ruf A., Barlage S., Tschope D., Clemetson KJ, Goodal AH, Michelson AD, Nurden AT, Shankey TV (1998). European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterization of platelet function . Thromb Haemostasis79: 885-896.22.
33.
Shattil S., Cunningham M., Hoxie JA (1987). Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies. Blood70: 307-315.
34.
Shattil SJ, Kashiwagi H., Pampori N. (1998). Integrin signaling: The platelet paradigm. Blood92: 2645-2657.
35.
Thakur ML, Walsh L., Joist JH (1976). Indium-111-labeled human platelets: Studies on preparation and evalution of in vitro and in vivo functions. Thromb Res9: 345-359.
36.
Vorchheimer DA, Fluster V. (1998). Oral platelet glycoprotein IIb/ IIIa receptor antagonists: The present challenge is safety . Circulation97: 312-321.
37.
Weiss DJ, Evanson OA, Wells RE (1997). Evaluation of arginine-glycine-aspartate-containing peptides as inhibitors of equine platelet function. Am J Vet Res58: 457-460.
38.
Weiss DJ, Geor RJ, Johnston G., Trent AM (1994). Microvascular thrombosis associated with onset of acute laminitis in ponies. Am J Vet Res55: 606-612.
